iX Biopharma said it has opened its Entity flagship store on JD Worldwide, JD.com’s cross-border e-commerce platform.

JD Worldwide provides a platform for Chinese consumers to purchase authentic imported products and enables international suppliers to sell directly to Chinese consumers without requiring an established presence in China.

Chinese consumers will have access to the full range of Entity nutraceuticals on the Entity JD Worldwide store. These include leading products


RestoriX® , a nicotinamide supplement which helps to increase levels of NAD+ (nicotinamide adenine dinucleotide) in the body needed for important cellular functions like energy metabolism, to counter the process of ageing and boost energy levels and vitality; and

LumeniX® , a sublingual glutathione wafer. Glutathione is the master antioxidant that helps the body to build stronger immunity to protect against viral infections. LumeniX® offers this, and also promotes skin fairness.

The launch of the JD Worldwide flagship store is the first foray into the Chinese market by Entity, the nutraceuticals division of iX Biopharma.

This is the first time Entity nutraceuticals will be sold directly to Chinese consumers through an external e-commerce platform, marking an exciting milestone for the Group.

Target: Chinese consumers


“China is a high priority market for us. Australian-made health supplements such as Entity are regarded by Chinese consumers as the gold standard of healthcare products due to Australia’s reputation for safety and quality. The launch of our Entity JD Worldwide store will now allow Chinese consumers close and convenient access to our products without having to travel to Australia.”

-- Eva Tan (photo),
Director of Corporate and Commercial Strategy of iX Biopharma

Entity is also preparing a launch of its flagship store on Tmall Global next week.

JD and Tmall are the two largest e-commerce platforms in China, commanding over 85% of the total B2C e-commerce market in China.

Entity nutraceuticals are developed and formulated by Australian scientists and manufactured in the Group’s TGA approved, cGMP-compliant manufacturing facility located in Victoria, Australia.

iX Biopharma said its Entity nutraceuticals are sold in more than 250 pharmacies and health food shops in Sydney, Melbourne and Perth, Australia.

Stock price 

15 c

52-week range

13 – 29 c

Market cap

S$98 m

PE (ttm)


Dividend yield 


1-year return


Shares outstanding

649 m

Source: Bloomberg

Entity nutraceuticals are natural, clinically-supported formulations.

Generic vitamin and mineral supplements that are widely available in the market serve to replenish nutritional deficiencies of a non-ideal diet.

iX Biopharma said Entity nutraceuticals, on the other hand, are designed to produce beneficial and perceptible improvement to a specific condition, and form an important part of a healthcare strategy to prevent more serious diseases.

Entity products are available in Singapore also via its website https://www.entity-health.com/about/

Share Prices

Counter NameLastChange
AEM Holdings3.3800.040
Avi-Tech Electronics0.4400.005
Best World Int.1.360-
China Sunsine0.400-
CNMC GoldMine0.280-0.005
CSE Global0.440-0.005
Food Empire0.580-0.005
Golden Energy0.151-
GSS Energy0.0480.001
ISDN Holdings0.370-0.010
IX Biopharma0.240-0.005
JB Foods0.575-0.025
KSH Holdings0.310-0.005
Medtecs Intl1.150-0.030
Moya Asia0.062-0.002
Nordic Group0.2200.010
Oxley Holdings0.210-
REX International0.134-0.006
Sri Trang Agro1.5100.010
Straco Corp.0.495-
Sunningdale Tech1.550-0.070
Sunpower Group0.6000.015
The Trendlines0.083-0.001
UG Healthcare0.905-0.015
Uni-Asia Group0.400-
Yangzijiang Shipbldg0.920-

NextInsight RSS

rss_2 NextInsight - Latest News

Online Now

We have 1118 guests and one member online

  • admin2